drugset / Trial / NCT01517880
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA).
Timeline
- Start
- 2012-05
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sialic Acid Extended Release | Unknown | 3000 mg | — |
| Subject | Sialic Acid Extended Release | Unknown | 6000 mg | — |